<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685698</url>
  </required_header>
  <id_info>
    <org_study_id>TG-873870-04</org_study_id>
    <nct_id>NCT00685698</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections</brief_title>
  <official_title>An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety and efficacy of TG-873870 (Nemonoxacin) in patients with
      Diabetic Foot Infections. Pharmacokinetic (PK) and pharmacodynamic (PD) assessment will be
      conducted in a subgroup of eight consenting patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success (in ITT Population)</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological Success Rate</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>Microbiological Success
Eradicated, defined as absence of the original pathogen(s) from a repeat culture of the original infection site performed at the TOC visit.
Presumed Eradicated, defined as meeting the definition for Clinical Success at the TOC visit, but tissue sample could be obtained for culture from the original infection site.
TOC=Test of Cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success (in PP Population)</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success (at End of Treatment/Early Termination)</measure>
    <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-Pathogen Clinical Responses (at Test of Cure)</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-Pathogen Clinical Response (at End of Treatment/Early Termination)</measure>
    <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at at End of Treatment/Early Termination within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-Pathogen Microbiological Responses</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>Microbiological responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Microbiological Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Microbiological Success rates for Streptococcus pyogenes in the PP population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Wound Score (at Test of Cure in ITT Population)</measure>
    <time_frame>Visit 1 (Baseline); Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Wound Score (at Test of Cure in PP Population)</measure>
    <time_frame>Visit 1 (Baseline); Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Wound Score (at End of Treatment/ Early Termination in ITT Population)</measure>
    <time_frame>Visit 1 (Baseline); End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and End of Treatment/ Early Termination visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Wound Score (at End of Treatment/ Early Termination in PP Population)</measure>
    <time_frame>Visit 1 (Baseline); End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population</measure>
    <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population</measure>
    <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)</measure>
    <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)</measure>
    <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
    <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)</measure>
    <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
    <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Foot Infections</condition>
  <arm_group>
    <arm_group_label>Nemonoxacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-873870 (Nemonoxacin)</intervention_name>
    <description>750 mg</description>
    <arm_group_label>Nemonoxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight ≥ 40 kg

          -  Previously known or newly diagnosed diabetes mellitus, including type 1 and type 2
             (per the American Diabetes Association guidelines), which is controlled by proper
             lifestyle (diet, exercise) or treatment with either oral medications or insulin

          -  Patients' HbA1c ≦ 12% at screening

          -  Clinically defined diabetic foot infection of mild or moderate severity (PEDIS grade
             2-3) as based on the guideline of the Infectious Diseases Society of America. It
             includes any inframalleolar infection of the soft-tissue, such as paronychia,
             cellulitis, myositis, abscesses, and tendonitis

          -  Evidence of necrotic tissue, purulent collections or abscess that may require
             excision, incision or drainage (based on investigator's judgment, and a surgeon if
             needed)

          -  Must be able to provide suitable tissue specimens (preferably obtained by biopsy or
             tissue curettage, or purulent fluid aspiration, rather than by swabbing) from the
             infected wound (after appropriate cleansing and debridement) for Gram-staining and
             bacterial cultures (aerobes and anaerobes)

          -  A confirmed Gram-positive pathogen infection by Gram-stain. The criterion to determine
             patient's eligibility for study recruitment is a Gram-stained smear with at least 1
             Gram-positive organism seen in at least two high power fields. A solely Gram-positive
             pathogen infection or a polymicrobial infection including Gram-positive and
             Gram-negative pathogens are acceptable within the framework of the study

        Exclusion Criteria:

          -  A co-morbid disease condition that could compromise evaluation or participation in
             this study, such as severe hepatic disease (e.g., active hepatitis, decompensated
             liver cirrhosis), renal failure (estimated creatinine clearance [CrCl] &lt;30 ml/minute
             or need for hemodialysis or peritoneal dialysis), or active systemic malignancy
             (advanced or metastatic), unless enrollment is deemed appropriate at the discretion of
             the Investigator with prior consultation with the study Medical Monitor

          -  History of prolonged QTc interval or a medical condition requiring the use of a
             concomitant medication that is associated with an increased QTc interval (e.g., class
             I or class III anti-arrhythmic agents)

          -  Contact dermatitis over the infected skin area, infected third-degree burn wounds,
             necrotizing fascitis, extensive gangrene, pyoderma gangrenosum, deep vein thrombosis,
             shock, or any medical disorder that could either interfere with the evaluation of
             treatment or the response of the patient to therapy

          -  Radiological evidence of bone or joints infection within 7 days prior to or at
             screening, i.e. potential osteomyelitis or septic arthritis

          -  Clinically defined uninfected or severe infection (PEDIS grade 1 or 4) as based on the
             Infectious Diseases Society of America classification system

          -  Any known severe immunosuppressive condition, such as an active hematological
             malignancy, HIV infection or active treatment with any immunosuppressive drug
             (including corticosteroids at a dose of &gt;20 mg/day of prednisone, or its equivalent)

          -  Has received or will be receiving chemotherapy or oncolytics within six months prior
             to entering or during the study

          -  History of current or active alcohol abuse (&gt;3 drinks daily or binge drinking) or any
             illicit drug use

          -  Known or suspected critical ischemia of the affected limb (based on investigators'
             clinical judgments and vascular assessment)

          -  Wound that contains or is proximate to any prosthetic materials or devices that is/are
             not scheduled for removal

          -  Patient with a foot infection that, in the investigator's judgment, is severe enough
             to require hospitalization or intravenous antibiotic therapy

          -  Neutrophil count &lt;1000 cells/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuang-Chung Shih, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Tri-Service General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jawl-Shan Hwang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cheng-Gung Memorial Hospital - LinKou, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Te-Lin Hsia, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardinal Tien Hospital (CTH), Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung-Fu Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital- Kaoshiung, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chien-Wen Chou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chi-Mei Medical Center, Tainan, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Che-Han Hsu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cheng Ching Hospital, Taichung, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph De Santo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HealthCare Partners, Pasadena, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Rogers, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Amputation Prevention Center at Broadlawns Medical Center, Des Moines, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwei Quartey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HealthCare Partners, Montebello, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn Tudhope, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montana Hospital, Pretoria, South Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andre Tudhope, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jubilee Clinical Trial Center, Hammanskraal, South Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Fulat, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastmed Academic Clinical Trial Center, East Lynne, South Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirkie van Rensburg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park Medical Center, Witbank, South Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mashra Gani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercantile Clinical Trial Center, Korsten, South Africa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piroon Mootsitkapun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Khon Kaen University, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chieh-Feng Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wan Fang Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HealthCare Partners</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthCare Partners</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Amputation Prevention Center at Broadlawns Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastmed Academic Clinical Trial Center</name>
      <address>
        <city>East Lynne</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jubilee Clinical Trial Center</name>
      <address>
        <city>Hammanskraal</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Medical Center</name>
      <address>
        <city>Witbank</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercantile Clinical Trial Center</name>
      <address>
        <city>Korsten</city>
        <state>Port Elizabeth</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital- Kaoshiung, Taiwan</name>
      <address>
        <city>Kaoshiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Ching Hospital, Taichung, Taiwan</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Center, Tainan, Taiwan</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Tien Hospital (CTH), Taiwan</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital, Taipei, Taiwan</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng-Gung Memorial Hospital - LinKou, Taiwan</name>
      <address>
        <city>Tao Yuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <results_first_submitted>December 16, 2014</results_first_submitted>
  <results_first_submitted_qc>December 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2015</results_first_posted>
  <last_update_submitted>December 25, 2014</last_update_submitted>
  <last_update_submitted_qc>December 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot Infections, DFI, Nemonoxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Focal Infection</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were assessed during the 1- to 2-day screening phase (Visit 1) to determine their eligibility. Eligible patients demonstrating the presence of at least one Gram-positive organism on the basis of Gram-stain could begin treatment with study medication the same day (Day 1, Visit 1).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nemonoxacin</title>
          <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>CULTURE GRAM NEG SPECIES</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>CULTURE RESULTS: GRAM-VE</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>NO GRAM POSITIVE CULTURE GROWN</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The ITT population consists of all patients from the Enrolled population who took at least one whole dose of study medication (three capsules) and who exhibited at least one Gram-positive pathogen at Baseline (Visit 1) as confirmed by culture of wound tissue by the central (or local) laboratory.</population>
      <group_list>
        <group group_id="B1">
          <title>Nemonoxacin</title>
          <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" lower_limit="39" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 20 and &lt; 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 30 and &lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40 and &lt; 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50 and &lt; 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 60 and &lt; 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 70 and &lt; 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Most patients (66.7%) were male.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Most patients (45.5%) were white.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Diabetes</title>
          <description>Most patients (90.9%) were type 2 diabetes.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type 1 (Juvenile Onset)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2 (Adult Onset)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since Diabetes Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distribution of Time Since Diabetes Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 5 and &lt; 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 10 and &lt; 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 20 and &lt; 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 30 and &lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Most Recent HbA1c % Result</title>
          <description>Performed within 6 Months prior to Visit 1.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 6.5% and &lt; 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 7.0% and &lt; 9.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 9.0% and &lt; 10.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 10.0% and &lt; 11.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 11.0% and &lt; 12.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 12.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c % Result at Visit 1</title>
          <description>Central Laboratory Data if available. Local Laboratory Data if not available. Most patients (54.5%) had a baseline HbA1c value between 7.0 and 9.0%, and 24.2% (8/33) appeared to be well controlled with values below 7.0%.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 6.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 6.5% and &lt; 7.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 7.0% and &lt; 9.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 9.0% and &lt; 10.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 10.0% and &lt; 11.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 11.0% and &lt; 12.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 12.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current treatment for Diabetes</title>
          <description>Most patients (75.8%) received oral agent(s) for their treatment of diabetes, and nearly half the patients were on insulin.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diet and Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since Diabetes Diagnosis</title>
          <description>The patient population included some newly diagnosed individuals.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Success (in ITT Population)</title>
        <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <population>All eligible patients who took at least one whole dose of study drug and had at least 1 gram-positive pathogen identified at the Baseline Visit (Visit 1).</population>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success (in ITT Population)</title>
          <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
          <population>All eligible patients who took at least one whole dose of study drug and had at least 1 gram-positive pathogen identified at the Baseline Visit (Visit 1).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="78.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Success Rate</title>
        <description>Microbiological Success
Eradicated, defined as absence of the original pathogen(s) from a repeat culture of the original infection site performed at the TOC visit.
Presumed Eradicated, defined as meeting the definition for Clinical Success at the TOC visit, but tissue sample could be obtained for culture from the original infection site.
TOC=Test of Cure</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (ITT Population at Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (PP Population at Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Success Rate</title>
          <description>Microbiological Success
Eradicated, defined as absence of the original pathogen(s) from a repeat culture of the original infection site performed at the TOC visit.
Presumed Eradicated, defined as meeting the definition for Clinical Success at the TOC visit, but tissue sample could be obtained for culture from the original infection site.
TOC=Test of Cure</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="61.2" upper_limit="95.0"/>
                    <measurement group_id="O2" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success (in PP Population)</title>
        <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <population>All eligible patients who took at least one whole dose of study drug and had at least 1 gram-positive pathogen identified at the Baseline Visit (Visit 1), and adhered to the protocol without major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success (in PP Population)</title>
          <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
          <population>All eligible patients who took at least one whole dose of study drug and had at least 1 gram-positive pathogen identified at the Baseline Visit (Visit 1), and adhered to the protocol without major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success (at End of Treatment/Early Termination)</title>
        <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
        <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (ITT Population at EOT/ET)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (PP Population at EOT/ET)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success (at End of Treatment/Early Termination)</title>
          <description>Clinical Success
Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.
Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="85.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-Pathogen Clinical Responses (at Test of Cure)</title>
        <description>Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (ITT Population at Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (PP Population at Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Per-Pathogen Clinical Responses (at Test of Cure)</title>
          <description>Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Escherichia coli (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterococcus faecalis (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus agalactiae (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pyogenes (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="NA">Insufficient numbers prevented reporting Clinical Success rate for Streptococcus pyogenes in the PP population.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-Pathogen Clinical Response (at End of Treatment/Early Termination)</title>
        <description>Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at at End of Treatment/Early Termination within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population.</description>
        <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (ITT Population at EOT/ET)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (PP Population at EOT/ET)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Per-Pathogen Clinical Response (at End of Treatment/Early Termination)</title>
          <description>Clinical responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Clinical Responses were assessed at at End of Treatment/Early Termination within each of the ITT and PP populations. Insufficient numbers prevented reporting Clinical Success rates for Streptococcus pyogenes in the PP population.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Staphylococcus aureus (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="81.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Escherichia coli (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterococcus faecalis (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus agalactiae (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pyogenes (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="NA">Insufficient numbers prevented reporting Clinical Success rate for Streptococcus pyogenes in the PP population.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-Pathogen Microbiological Responses</title>
        <description>Microbiological responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Microbiological Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Microbiological Success rates for Streptococcus pyogenes in the PP population.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (ITT Population at Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (PP Population at Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Per-Pathogen Microbiological Responses</title>
          <description>Microbiological responses were assessed on a per-pathogen basis for the most frequently isolated pathogens at baseline (i.e., present in four or more patients), including MRSA. Microbiological Responses were assessed at Test of Cure visit within each of the ITT and PP populations. Insufficient numbers prevented reporting Microbiological Success rates for Streptococcus pyogenes in the PP population.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Staphylococcus aureus (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="68.1" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="73.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Escherichia coli (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enterococcus faecalis (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus agalactiae (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pyogenes (in ITT population)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="NA">Insufficient numbers prevented reporting Microbiological Success rate for Streptococcus pyogenes in the PP population.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Wound Score (at Test of Cure in ITT Population)</title>
        <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
        <time_frame>Visit 1 (Baseline); Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (at Baseline, ITT Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (at Test of Cure Visit, ITT Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O3">
            <title>Nemonoxacin (Change From Baseline to Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Wound Score (at Test of Cure in ITT Population)</title>
          <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="6.30"/>
                    <measurement group_id="O2" value="6.0" spread="3.67"/>
                    <measurement group_id="O3" value="-11.2" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Wound Score (at Test of Cure in PP Population)</title>
        <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
        <time_frame>Visit 1 (Baseline); Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (at Baseline, PP Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (at Test of Cure Visit, PP Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O3">
            <title>Nemonoxacin (Change From Baseline to Test of Cure Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Wound Score (at Test of Cure in PP Population)</title>
          <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="6.54"/>
                    <measurement group_id="O2" value="5.0" spread="2.79"/>
                    <measurement group_id="O3" value="-12.9" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Wound Score (at End of Treatment/ Early Termination in ITT Population)</title>
        <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and End of Treatment/ Early Termination visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
        <time_frame>Visit 1 (Baseline); End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (at Baseline, ITT Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (at EOT/ET Visit, ITT Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O3">
            <title>Nemonoxacin (Change From Baseline to EOT/ET Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Wound Score (at End of Treatment/ Early Termination in ITT Population)</title>
          <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and End of Treatment/ Early Termination visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="6.30"/>
                    <measurement group_id="O2" value="7.2" spread="4.65"/>
                    <measurement group_id="O3" value="-9.6" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Wound Score (at End of Treatment/ Early Termination in PP Population)</title>
        <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
        <time_frame>Visit 1 (Baseline); End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin (at Baseline, PP Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O2">
            <title>Nemonoxacin (at EOT/ET Visit, PP Population)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
          <group group_id="O3">
            <title>Nemonoxacin (Change From Baseline to EOT/ET Visit)</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total Wound Score (at End of Treatment/ Early Termination in PP Population)</title>
          <description>The Diabetic Foot Infection (DFI) Wound Scores will be used to evaluate the wound assessment at baseline and Test of Cure visits. The wound composite score was based on combining the general wound parameters (signs and symptoms of infection), and wound measurements (length, width, depth). Each wound parameter was assigned a score based on severity, with higher scores defining greater severity. For wound measurements and undermining, larger measurements received higher scores. The minimum and maximum score are 3 and 49, respectively.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="6.54"/>
                    <measurement group_id="O2" value="6.2" spread="4.31"/>
                    <measurement group_id="O3" value="-12.1" spread="6.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population</title>
        <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination.</description>
        <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population</title>
          <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Uninfected to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population</title>
        <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population</title>
          <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Uninfected to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population</title>
        <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination.</description>
        <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population</title>
          <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and End of Treatment/Early Termination.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Uninfected to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population</title>
        <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population</title>
          <description>The number of patients within each of the PEDIS grading categories (uninfected, mild, moderate and severe) at baseline and Test of Cure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Uninfected to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uninfected to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Uninfected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe to Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)</title>
        <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination.</description>
        <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <population>Number at the End of Treatment/Early Termination Visit, ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)</title>
          <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination.</description>
          <population>Number at the End of Treatment/Early Termination Visit, ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surgery Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or Additional Antibiotic Therapy Required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)</title>
        <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <population>Number at Test of Cure Visit, ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)</title>
          <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure.</description>
          <population>Number at Test of Cure Visit, ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surgery Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or Additional Antibiotic Therapy Required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)</title>
        <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination.</description>
        <time_frame>End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)</title>
          <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at End of Treatment/Early Termination.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surgery Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or Additional Antibiotic Therapy Required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)</title>
        <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure.</description>
        <time_frame>Test of Cure Visit, 12±2 days after End of Treatment Visit/Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nemonoxacin</title>
            <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)</title>
          <description>Results in relation to the need for surgery, hospitalization, new and/or additional non-study antibiotic therapy for failure of initial oral therapy at Test of Cure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Surgery Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation Required for DFI During Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New or Additional Antibiotic Therapy Required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study period (Visit 1 to Test of Cure)</time_frame>
      <desc>At each visit, the Investigator will determine whether any adverse events have occurred. The patients will be questioned in a general way and no specific symptoms will be suggested. None of the SAEs were considered related to study drug. No patient died during the study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nemonoxacin</title>
          <description>Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
TG-873870 (Nemonoxacin): 750 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>BLOOD ALBUMIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>CREATININE RENAL CLEARANCE DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>PERSONALITY CHANGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>INCREASED UPPER AIRWAY SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>THROAT TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>SWELLING FACE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI needs to inform sponsor and asks for permission before he/she discusses or publishes trial results after the trial is completed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chen-En Tsai, M.D., Ph.D.</name_or_title>
      <organization>TaiGen Biotechnology Co., Ltd.</organization>
      <phone>+886-2-8177-7072 ext 1211</phone>
      <email>cetsai@taigenbiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

